Bristol-Myers Squibb Company (BMY) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $58.66 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%).
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, operating in a single segment. It sells products globally with 69% of revenues from the United States in 2025, generating $48.2... Read more
Sell if holding. Analyst target reached at $58.66 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%). Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.9/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States69%10-K Item 1: 'United States| 69 | %| | 71 | %| | 69 | %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $58.66 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%). Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $55.76. Score 5.9/10, moderate confidence.
Take-profit target: $59.56 (+1.5% upside). Prior stop was $55.76. Stop-loss: $55.76.
Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.2): -1.5.
Bristol-Myers Squibb Company trades at a P/E of 17.0 (forward 9.9). TrendMatrix value score: 7.0/10. Verdict: Sell.
36 analysts cover BMY with a consensus score of 3.5/5. Average price target: $63.
What does Bristol-Myers Squibb Company do?Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology,...
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, operating in a single segment. It sells products globally with 69% of revenues from the United States in 2025, generating $48.2 billion in total revenues.